The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in
cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins …

KRAS is the most frequently mutated oncogene in cancer. Activating mutations in codon 12,
especially G12D, have the highest prevalence across a range of carcinomas and …

Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid
tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for …

Oncogenic driver mutations have implications that extend beyond cancer cells themselves.
Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti …

Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have
become the frontier of cancer treatment and successfully prolonged the survival of patients …

Simple Summary For non-small-cell lung cancer (NSCLC) patients undergoing
immunotherapy blocking the PD-1/PD-L1 interaction, the cancer cell PD-L1 expression level …

The RAS gene family is one of the most frequently mutated oncogenes in human cancers. In
KRAS, mutations of G12D and G12C are common. Here, 52 iridoids were selected and …

KRAS mutations are among the most commonly occurring mutations in cancer. After being
deemed undruggable for decades, KRAS G12C specific inhibitors showed that small …

Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long
been recognized as “undruggable”. KRAS mutations frequently occur in multiple human …